ArticleTranslational oncology2026
Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the synergistic potential of TROP-2-targeted CAR-T cells combined with the vascular disrupting agent PLG-g-mPEG/CA4/BLZ945 (CBP). We hypothesized that CBP would disrupt the tumor neovascular, thereby enhancing infiltration of the CAR-T cells.
methodsAnalyzed TROP-2 expression in breast cancer using bioinformatics, qRT-PCR, and sequencing. Constructed and evaluated TROP-2 CAR-T cells in vitro. Finally, we prepared an animal model of breast cancer, and verified the anti-tumor therapeutic effect, safety evaluation and biologic mechanisms of TROP-2 CAR-T combined with CBP in vivo.
resultsBioinformatics analysis and in vitro experiments showed that TROP-2 was widely expressed in breast cancer cells. The successfully constructed TROP-2 CAR-T cells exhibited high cytotoxicity in vitro. The experimental results in mice showed that the combination therapy of CBP and TROP-2 CAR-T significantly enhanced the anti-tumor effect, and no significant decrease in survival rate or major organ damage was observed. Mechanism studies have shown that the anti-tumor effect of the combination therapy group may be related to immune cell infiltration, CAR-T cell infiltration, and upregulation of immune related factors.
conclusionOur findings demonstrated the potential of TROP-2 as a viable target for CAR-T therapy in breast cancer. The combination of TROP-2 CAR-T cells with CBP not only enhances the therapeutic efficacy but also maintains a favorable safety profile, offering a promising new strategy for the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.